Palmitoylethanolamide, safety and efficacy articles and reviews from professor JMK Hesselink, MD
In 2010 in Athens at the 3rd International Congress on Neuropathic Pain Keppel Hesselink identified a remarkable poster in the basements of the congres. It was a poster from the group of professor Cruccu in Rome, and the poster described the clinical findings in diabetic neuropathy of a hitherto to him and all his English speaking colleagues unknown natural compound, palmitoylethanolamide (PEA). Prof. Keppel Hesselink worked as a VP many years at Bayer AG, and was responsable for the world wide development of CNS drugs. He said that never in his carrier he came across a molecule so interesting as PEA.
Palmitoylethanolamide: amazing compound
This compound had amazing clinical effects and a remarkable safety and tolerability profile. It has been known before in oldfashioned matrix tablet and suspension formulation, but since 2007 it was available in an improved formulation: micro-PEA, specially designed to improve the bioavailability of PEA (currently available as formulations containing micronized PEA-m, ultramicronized PEA-um or optimized PEA-opt).
Palmitoylethanolamide had been in the dark since clinical work started with the compound in the 70s of last century, because nearly all research and development was done in Italy, and no clinical data were published in English.
Keppel Hesselink’s goal was to disclose this unique natural compound for the clinical world, since its first identification as an analgesic in 1966. He did so with a number of publications from 2011 onwards, all referred to in this entry.
Micro-PEA: new PEA formulation in specific formulations
Therefore he started in 2010 to work with the compound in his institute, treated many hundreds of patients with formulations containing micro-PEA, and published a great number of original articles, case-reports, clinical trials and reviews on this compound we summarize here for you in this entry, including links to most of the original papers.
- Keppel Hesselink JM. Palmitoylethanolamid and Other Lipid Autacoids Against Neuroinflammation, Pain, and Spasms in Multiple Sclerosis. Chapter 4 in Book: Ronald Ross Watson & William Killgore (eds) Nutrition and Lifestyle in Neurological Autoimmune Diseases https://dx.doi.org/10.1016/B978-0-12-805298-3.00004-9, to be published in 2017
- Keppel Hesselink JM. Palmitoylethanolamide: research synergy between academia and industry, based on insights and work of Nobel laureate Rita Levi-Montalcini. Journal of Clinical Trials & Patenting, 2016, 1,1:3
- Keppel Hesselink JM, Chiosi F, Costagliola C. Resolvins and aliamides: lipid autacoids in ophthalmology – what promise do they hold. Drug Design, Development and Therapy, 2016;10:1-9
- Keppel Hesselink JM, Kopsky DJ, Sjalben N. New topical treatment of vulvodynia based on the pathogenetic role of cross talk between nociceptors, immunocompetent cells, and epithelial cells. Journal of Pain Research, 2016, accepted.
- Keppel Hesselink JM, Kopsky DJ. The Role of Palmitoylethanolamide, an Autacoid, in the Symptomatic Treatment of Muscle Cramps: Three Case Reports and Review of Literature. J Clin Case Rep 2016; 6: 744. doi:10.4172/2165-7920.1000744
- Keppel Hesselink JM. Autacoids: A New Fundament for Pain Medicine of the 21th Century. Anaesthesia, Critical Care and Pain Management 2016; 1: 3-6 FULL PAPER: 2016-autacoids
- Keppel Hesselink JM. Palmitoylethanolamide and other Lipid Autacoids in the Treatment of Chronic Pain: A New Chapter in Pain Medicine.J Mol Histol Med Physiol 2016, 1:2:
- Keppel Hesselink, JM. Use of the Analgesic, Anti-inflammatory and Neuroprotectant Supplement. Palmitoylethanolamide in the Tarsal Tunnel Syndrome. Clinical Research on Foot & Ankle. Clin Res Foot Ankle 2015, 3:1: https://www.esciencecentral.org/journals/2329-910X-1000e105.pdf
- Keppel Hesselink JMK, Kopsky DJ, Witkamp RF. Palmitoylethanolamide (PEA)-‘promiscuous’ anti-inflammatory and analgesic molecule at the interface between nutrition and pharma, Pharma Nutrition(2013), https://dx.doi.org/10.1016/ j.phanu.2013.11.127
- Keppel Hesselink JM. Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. Int Med Case Rep J. 2013 Sep 13;6:49-53. doi: 10.2147/IMCRJ.S51572.
- J. M. Keppel Hesselink, Tineke de Boer, and Renger F. Witkamp, Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold, International Journal of Inflammation, vol. 2013, Article ID 151028, 8 pages, 2013. doi:10.1155/2013/151028
- Keppel Hesselink JM. Clinical neuro-restaurative effects of palmitoylethanolamide due to Inhibition of inhibition of NF-kappaB?. Journal of Neuroinflammation 2013, 10:92 doi:10.1186/1742-2094-10-92
- Keppel Hesselink, JM. Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical. J Pain Res August 2013 Volume 2013: 625 – 634
- Keppel Hesselink JM. Anti-inflammatory compounds, such as ketamine and palmitoylethanolamide as antidepressants. Journal of Neuroinflammation 2013, 10:43 doi:10.1186/1742-2094-10-43
- Keppel Hesselink JM. Professor Rita Levi-Montalcini on Nerve Growth Factor, Mast Cells and Palmitoylethanolamide, an Endogenous Anti-Inflammatory and Analgesic Compound. J Pain Relief 2013, 2:1 https://dx.doi.org/10.4172/2167-0846.100011
- Keppel Hesselink JM, Hekker TA, Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series Journal of Pain Research 2012 Volume 2012:5 Pages 437 – 442
- Keppel Hesselink JM, Kopsky DJ. Treatment of Chronic Regional Pain Syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of non-neuronal cells” J Pain Res. 2013 Mar 21;6:239-45. doi: 10.2147/JPR.S42417. Print 2013.
- Keppel Hesselink, JM (2012) New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. Open Pain Journal 2012, 5: 12-23
- Kopsky DJ, Keppel Hesselink, JM. Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. Acupunct Med. 2012 Mar; 30(1):53-5.
- Keppel Hesselink, JM (2011) Glia as a new target for neuropathic pain, clinical proof of concept for palmitoylethanolamide, a glia-modulator.Anaesthesia , Pain & Intensive Care.
- Keppel Hesselink JM. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain. Eur J Obstet Gynecol Reprod Biol. 2011 Dec;159(2):488.